Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and x-linked protoporphyria

Manisha Balwani, Hetanshi Naik, Karl Anderson, D. Montgomery Bissell, Joseph Bloomer, Herbert L. Bonkovsky, John D. Phillips, Jessica R. Overbey, Bruce Wang, Ashwani K. Singal, Lawrence U. Liu, Robert J. Desnick

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

IMPORTANCE Autosomal recessive erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare photodermatoses presenting with variable degrees of painful phototoxicity that markedly affects quality of life. The clinical variability, determinants of severity, and genotype/phenotype correlations of these diseases are not well characterized. OBJECTIVE To describe the baseline clinical characteristics, genotypes, and determinants of disease severity in a large patient cohort with EPP or XLP. DESIGN, SETTING, AND PARTICIPANTS A prospective observational studywas conducted among patients with confirmed diagnoses of EPP or XLP from November 1, 2010, to December 6, 2015, at 6 academic medical centers of the Porphyrias Consortium of the National Institutes of Health Rare Diseases Clinical Research Network. Detailed medical histories, including history of phototoxicity and treatment, were collected on standardized case report forms. Patients underwent baseline laboratory testing, total erythrocyte protoporphyrin (ePPIX) testing, and molecular genetic testing. Data were entered into a centralized database. MAIN OUTCOMES AND MEASURES Results of biochemical and genetic testswere explored for association with clinical phenotype in patients with EPP or XLP. RESULTS Of the 226 patients in the study (113 female and 113 male patients; mean [SD] age, 36.7 [17.0] years), 186 (82.3%) had EPP with a FECH (OMIM 612386) mutation and the common low-expression FECH allele IVS3-48T>C, and only 1 patient had 2 FECH mutations. Twenty-two patients had XLP (9.7%; 10 male and 12 female patients), and 9 patients (4.0%) had elevated ePPIX levels and symptoms consistent with protoporphyria but no detectable mutation in the FECH or ALAS2 (OMIM 301300) gene. Samples of DNA could not be obtained from 8 patients. Patients' mean (SD) age at symptom onset was 4.4 (4.4) years. Anemia (107 [47.3%]), history of liver dysfunction (62 [27.4%]), and gallstones (53 [23.5%]) were commonly reported. Higher ePPIX levels were associated with earlier age of symptom onset (median ePPIX levels for those who developed symptoms before vs after 1 year of age, 1744 vs 1567 μg/dL; P = .02), less sun tolerance (median ePPIX levels for those reporting symptoms before vs after 10 minutes of sun exposure, 2233 vs 1524 μg/dL; P < .001), and increased risk of liver dysfunction (median ePPIX levels for those with liver dysfunction vs normal liver function, 2016 vs 1510 μg/dL; P = .003). Patients with EPP and FECH missense mutations had significantly lower ePPIX levels than those with other mutations (1462 vs 1702 μg/dL; P = .01). Male patients with XLP had significantly higher ePPIX levels, on average, than did patients with EPP (3574 vs 1669 μg/dL; P < .001). Marked clinical variability was seen in female patients with XLP owing to random X-chromosomal inactivation. CONCLUSIONS AND RELEVANCE These data suggest that higher ePPIX levels are a major determinant of disease severity and risk of liver dysfunction in patients with EPP or XLP. These findings provide a framework for clinical monitoring and management of these disorders.

Original languageEnglish (US)
Pages (from-to)789-796
Number of pages8
JournalJAMA Dermatology
Volume153
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Erythropoietic Protoporphyria
Molecular Biology
Liver Diseases
Phototoxic Dermatitis
Genetic Databases
Mutation
Solar System
Age of Onset
Porphyrias
X Chromosome Inactivation

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and x-linked protoporphyria. / Balwani, Manisha; Naik, Hetanshi; Anderson, Karl; Bissell, D. Montgomery; Bloomer, Joseph; Bonkovsky, Herbert L.; Phillips, John D.; Overbey, Jessica R.; Wang, Bruce; Singal, Ashwani K.; Liu, Lawrence U.; Desnick, Robert J.

In: JAMA Dermatology, Vol. 153, No. 8, 01.08.2017, p. 789-796.

Research output: Contribution to journalArticle

Balwani, M, Naik, H, Anderson, K, Bissell, DM, Bloomer, J, Bonkovsky, HL, Phillips, JD, Overbey, JR, Wang, B, Singal, AK, Liu, LU & Desnick, RJ 2017, 'Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and x-linked protoporphyria', JAMA Dermatology, vol. 153, no. 8, pp. 789-796. https://doi.org/10.1001/jamadermatol.2017.1557
Balwani, Manisha ; Naik, Hetanshi ; Anderson, Karl ; Bissell, D. Montgomery ; Bloomer, Joseph ; Bonkovsky, Herbert L. ; Phillips, John D. ; Overbey, Jessica R. ; Wang, Bruce ; Singal, Ashwani K. ; Liu, Lawrence U. ; Desnick, Robert J. / Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and x-linked protoporphyria. In: JAMA Dermatology. 2017 ; Vol. 153, No. 8. pp. 789-796.
@article{c1b38372111d4407891aaa82144e1a3e,
title = "Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and x-linked protoporphyria",
abstract = "IMPORTANCE Autosomal recessive erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare photodermatoses presenting with variable degrees of painful phototoxicity that markedly affects quality of life. The clinical variability, determinants of severity, and genotype/phenotype correlations of these diseases are not well characterized. OBJECTIVE To describe the baseline clinical characteristics, genotypes, and determinants of disease severity in a large patient cohort with EPP or XLP. DESIGN, SETTING, AND PARTICIPANTS A prospective observational studywas conducted among patients with confirmed diagnoses of EPP or XLP from November 1, 2010, to December 6, 2015, at 6 academic medical centers of the Porphyrias Consortium of the National Institutes of Health Rare Diseases Clinical Research Network. Detailed medical histories, including history of phototoxicity and treatment, were collected on standardized case report forms. Patients underwent baseline laboratory testing, total erythrocyte protoporphyrin (ePPIX) testing, and molecular genetic testing. Data were entered into a centralized database. MAIN OUTCOMES AND MEASURES Results of biochemical and genetic testswere explored for association with clinical phenotype in patients with EPP or XLP. RESULTS Of the 226 patients in the study (113 female and 113 male patients; mean [SD] age, 36.7 [17.0] years), 186 (82.3{\%}) had EPP with a FECH (OMIM 612386) mutation and the common low-expression FECH allele IVS3-48T>C, and only 1 patient had 2 FECH mutations. Twenty-two patients had XLP (9.7{\%}; 10 male and 12 female patients), and 9 patients (4.0{\%}) had elevated ePPIX levels and symptoms consistent with protoporphyria but no detectable mutation in the FECH or ALAS2 (OMIM 301300) gene. Samples of DNA could not be obtained from 8 patients. Patients' mean (SD) age at symptom onset was 4.4 (4.4) years. Anemia (107 [47.3{\%}]), history of liver dysfunction (62 [27.4{\%}]), and gallstones (53 [23.5{\%}]) were commonly reported. Higher ePPIX levels were associated with earlier age of symptom onset (median ePPIX levels for those who developed symptoms before vs after 1 year of age, 1744 vs 1567 μg/dL; P = .02), less sun tolerance (median ePPIX levels for those reporting symptoms before vs after 10 minutes of sun exposure, 2233 vs 1524 μg/dL; P < .001), and increased risk of liver dysfunction (median ePPIX levels for those with liver dysfunction vs normal liver function, 2016 vs 1510 μg/dL; P = .003). Patients with EPP and FECH missense mutations had significantly lower ePPIX levels than those with other mutations (1462 vs 1702 μg/dL; P = .01). Male patients with XLP had significantly higher ePPIX levels, on average, than did patients with EPP (3574 vs 1669 μg/dL; P < .001). Marked clinical variability was seen in female patients with XLP owing to random X-chromosomal inactivation. CONCLUSIONS AND RELEVANCE These data suggest that higher ePPIX levels are a major determinant of disease severity and risk of liver dysfunction in patients with EPP or XLP. These findings provide a framework for clinical monitoring and management of these disorders.",
author = "Manisha Balwani and Hetanshi Naik and Karl Anderson and Bissell, {D. Montgomery} and Joseph Bloomer and Bonkovsky, {Herbert L.} and Phillips, {John D.} and Overbey, {Jessica R.} and Bruce Wang and Singal, {Ashwani K.} and Liu, {Lawrence U.} and Desnick, {Robert J.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1001/jamadermatol.2017.1557",
language = "English (US)",
volume = "153",
pages = "789--796",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Clinical, biochemical, and genetic characterization of north American patients with erythropoietic protoporphyria and x-linked protoporphyria

AU - Balwani, Manisha

AU - Naik, Hetanshi

AU - Anderson, Karl

AU - Bissell, D. Montgomery

AU - Bloomer, Joseph

AU - Bonkovsky, Herbert L.

AU - Phillips, John D.

AU - Overbey, Jessica R.

AU - Wang, Bruce

AU - Singal, Ashwani K.

AU - Liu, Lawrence U.

AU - Desnick, Robert J.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - IMPORTANCE Autosomal recessive erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare photodermatoses presenting with variable degrees of painful phototoxicity that markedly affects quality of life. The clinical variability, determinants of severity, and genotype/phenotype correlations of these diseases are not well characterized. OBJECTIVE To describe the baseline clinical characteristics, genotypes, and determinants of disease severity in a large patient cohort with EPP or XLP. DESIGN, SETTING, AND PARTICIPANTS A prospective observational studywas conducted among patients with confirmed diagnoses of EPP or XLP from November 1, 2010, to December 6, 2015, at 6 academic medical centers of the Porphyrias Consortium of the National Institutes of Health Rare Diseases Clinical Research Network. Detailed medical histories, including history of phototoxicity and treatment, were collected on standardized case report forms. Patients underwent baseline laboratory testing, total erythrocyte protoporphyrin (ePPIX) testing, and molecular genetic testing. Data were entered into a centralized database. MAIN OUTCOMES AND MEASURES Results of biochemical and genetic testswere explored for association with clinical phenotype in patients with EPP or XLP. RESULTS Of the 226 patients in the study (113 female and 113 male patients; mean [SD] age, 36.7 [17.0] years), 186 (82.3%) had EPP with a FECH (OMIM 612386) mutation and the common low-expression FECH allele IVS3-48T>C, and only 1 patient had 2 FECH mutations. Twenty-two patients had XLP (9.7%; 10 male and 12 female patients), and 9 patients (4.0%) had elevated ePPIX levels and symptoms consistent with protoporphyria but no detectable mutation in the FECH or ALAS2 (OMIM 301300) gene. Samples of DNA could not be obtained from 8 patients. Patients' mean (SD) age at symptom onset was 4.4 (4.4) years. Anemia (107 [47.3%]), history of liver dysfunction (62 [27.4%]), and gallstones (53 [23.5%]) were commonly reported. Higher ePPIX levels were associated with earlier age of symptom onset (median ePPIX levels for those who developed symptoms before vs after 1 year of age, 1744 vs 1567 μg/dL; P = .02), less sun tolerance (median ePPIX levels for those reporting symptoms before vs after 10 minutes of sun exposure, 2233 vs 1524 μg/dL; P < .001), and increased risk of liver dysfunction (median ePPIX levels for those with liver dysfunction vs normal liver function, 2016 vs 1510 μg/dL; P = .003). Patients with EPP and FECH missense mutations had significantly lower ePPIX levels than those with other mutations (1462 vs 1702 μg/dL; P = .01). Male patients with XLP had significantly higher ePPIX levels, on average, than did patients with EPP (3574 vs 1669 μg/dL; P < .001). Marked clinical variability was seen in female patients with XLP owing to random X-chromosomal inactivation. CONCLUSIONS AND RELEVANCE These data suggest that higher ePPIX levels are a major determinant of disease severity and risk of liver dysfunction in patients with EPP or XLP. These findings provide a framework for clinical monitoring and management of these disorders.

AB - IMPORTANCE Autosomal recessive erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare photodermatoses presenting with variable degrees of painful phototoxicity that markedly affects quality of life. The clinical variability, determinants of severity, and genotype/phenotype correlations of these diseases are not well characterized. OBJECTIVE To describe the baseline clinical characteristics, genotypes, and determinants of disease severity in a large patient cohort with EPP or XLP. DESIGN, SETTING, AND PARTICIPANTS A prospective observational studywas conducted among patients with confirmed diagnoses of EPP or XLP from November 1, 2010, to December 6, 2015, at 6 academic medical centers of the Porphyrias Consortium of the National Institutes of Health Rare Diseases Clinical Research Network. Detailed medical histories, including history of phototoxicity and treatment, were collected on standardized case report forms. Patients underwent baseline laboratory testing, total erythrocyte protoporphyrin (ePPIX) testing, and molecular genetic testing. Data were entered into a centralized database. MAIN OUTCOMES AND MEASURES Results of biochemical and genetic testswere explored for association with clinical phenotype in patients with EPP or XLP. RESULTS Of the 226 patients in the study (113 female and 113 male patients; mean [SD] age, 36.7 [17.0] years), 186 (82.3%) had EPP with a FECH (OMIM 612386) mutation and the common low-expression FECH allele IVS3-48T>C, and only 1 patient had 2 FECH mutations. Twenty-two patients had XLP (9.7%; 10 male and 12 female patients), and 9 patients (4.0%) had elevated ePPIX levels and symptoms consistent with protoporphyria but no detectable mutation in the FECH or ALAS2 (OMIM 301300) gene. Samples of DNA could not be obtained from 8 patients. Patients' mean (SD) age at symptom onset was 4.4 (4.4) years. Anemia (107 [47.3%]), history of liver dysfunction (62 [27.4%]), and gallstones (53 [23.5%]) were commonly reported. Higher ePPIX levels were associated with earlier age of symptom onset (median ePPIX levels for those who developed symptoms before vs after 1 year of age, 1744 vs 1567 μg/dL; P = .02), less sun tolerance (median ePPIX levels for those reporting symptoms before vs after 10 minutes of sun exposure, 2233 vs 1524 μg/dL; P < .001), and increased risk of liver dysfunction (median ePPIX levels for those with liver dysfunction vs normal liver function, 2016 vs 1510 μg/dL; P = .003). Patients with EPP and FECH missense mutations had significantly lower ePPIX levels than those with other mutations (1462 vs 1702 μg/dL; P = .01). Male patients with XLP had significantly higher ePPIX levels, on average, than did patients with EPP (3574 vs 1669 μg/dL; P < .001). Marked clinical variability was seen in female patients with XLP owing to random X-chromosomal inactivation. CONCLUSIONS AND RELEVANCE These data suggest that higher ePPIX levels are a major determinant of disease severity and risk of liver dysfunction in patients with EPP or XLP. These findings provide a framework for clinical monitoring and management of these disorders.

UR - http://www.scopus.com/inward/record.url?scp=85027332575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027332575&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2017.1557

DO - 10.1001/jamadermatol.2017.1557

M3 - Article

VL - 153

SP - 789

EP - 796

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 8

ER -